Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1984 Nov;58(2):486–492.

Prevention of immune precipitation by purified classical pathway complement components.

J K Naama, A O Hamilton, A C Yeung-Laiwah, K Whaley
PMCID: PMC1577075  PMID: 6333948

Abstract

The role of the classical pathway of complement in the prevention of immune precipitation has been investigated using purified complement components and immune complexes (IC) consisting of rabbit anti-BSA and BSA. C1 reduced the rate of immune precipitation. As C1q, EDTA treated C1 or C1-inhibitor treated C1 were unable to retard the precipitation of IC, it was concluded that the intact C1 molecule was required for this function. Use of phenylmethylsulphonyl fluoride and benzamidine showed that the enzymatic site on C1 was not required for this activity. C4 and C2 did not affect immune precipitation significantly when C1 was present at the concentrations present in serum. When C3 was added to C1, C4 and C2 precipitation of IC did not occur. These data demonstrate that classical pathway activation alone is sufficient for the prevention of immune precipitation.

Full text

PDF
486

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolotin C., Morris S., Tack B., Prahl J. Purification and structural analysis of the fourth component of human complement. Biochemistry. 1977 May 3;16(9):2008–2015. doi: 10.1021/bi00628a039. [DOI] [PubMed] [Google Scholar]
  2. Campbell R. D., Dodds A. W., Porter R. R. The binding of human complement component C4 to antibody-antigen aggregates. Biochem J. 1980 Jul 1;189(1):67–80. doi: 10.1042/bj1890067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. El-Ghobarey A., Whaley K. Alternative pathway complement activation in rheumatoid arthritis. J Rheumatol. 1980 Jul-Aug;7(4):453–460. [PubMed] [Google Scholar]
  4. Gadd K. J., Reid K. B. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J. 1981 May 1;195(2):471–480. doi: 10.1042/bj1950471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kerr M. A., Porter R. R. The purification and properties of the second component of human complement. Biochem J. 1978 Apr 1;171(1):99–107. doi: 10.1042/bj1710099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kijlstra A., van Es L. A., Daha M. R. Effects of C-1 on the size of soluble immune aggregates and on their processing by macrophages. J Immunol. 1979 Aug;123(2):640–645. [PubMed] [Google Scholar]
  7. Laurell A. B., Johnson U., Mårtensson U., Sjöholm A. G. Formation of complexes composed of C1r, C1s, and C1 inactivator in human serum on activation of C1. Acta Pathol Microbiol Scand C. 1978 Dec;86C(6):299–306. doi: 10.1111/j.1699-0463.1978.tb02594.x. [DOI] [PubMed] [Google Scholar]
  8. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  9. McPhaden A. R., Whaley K. Modulation of C2 biosynthesis by antigen-antibody complexes. J Clin Lab Immunol. 1982 Jan;7(1):15–19. [PubMed] [Google Scholar]
  10. Møller N. P. Fc-mediated immune precipitation. I. A new role of the Fc-portion of IgG. Immunology. 1979 Nov;38(3):631–640. [PMC free article] [PubMed] [Google Scholar]
  11. Møller N. P., Steensgaard J. Fc-mediated immune precipitation. II. Analysis of precipitating immune complexes by rate-zonal ultracentrifugation. Immunology. 1979 Nov;38(3):641–648. [PMC free article] [PubMed] [Google Scholar]
  12. Naama J. K., Mitchell W. S., Zoma A., Veitch J., Whaley K. Complement-mediated inhibition of immune precipitation in patients with immune complex diseases. Clin Exp Immunol. 1983 Feb;51(2):292–298. [PMC free article] [PubMed] [Google Scholar]
  13. Polley M. J., Müller-Eberhard H. J. Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med. 1967 Dec 1;126(6):1013–1025. doi: 10.1084/jem.126.6.1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reboul A., Arlaud G. J., Sim R. B., Colomb M. G. A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s. FEBS Lett. 1977 Jul 1;79(1):45–50. doi: 10.1016/0014-5793(77)80347-5. [DOI] [PubMed] [Google Scholar]
  15. Rodwell J. D., Lih-Heng-Tang, Schumaker V. N. Antigen valence and Fc-localized secondary forces in antibody precipitation. Mol Immunol. 1980 Dec;17(12):1591–1597. doi: 10.1016/0161-5890(80)90185-6. [DOI] [PubMed] [Google Scholar]
  16. Schifferli J. A., Bartolotti S. R., Peters D. K. Inhibition of immune precipitation by complement. Clin Exp Immunol. 1980 Nov;42(2):387–394. [PMC free article] [PubMed] [Google Scholar]
  17. Schifferli J. A., Peters D. K. Complement, the immune-complex lattice, and the pathophysiology of complement-deficiency syndromes. Lancet. 1983 Oct 22;2(8356):957–959. doi: 10.1016/s0140-6736(83)90464-6. [DOI] [PubMed] [Google Scholar]
  18. Schifferli J. A., Woo P., Peters D. K. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clin Exp Immunol. 1982 Mar;47(3):555–562. [PMC free article] [PubMed] [Google Scholar]
  19. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]
  20. Tack B. F., Morris S. C., Prahl J. W. Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry. 1979 Apr 17;18(8):1490–1497. doi: 10.1021/bi00575a016. [DOI] [PubMed] [Google Scholar]
  21. Takahashi M., Tack B. F., Nussenzweig V. Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med. 1977 Jan 1;145(1):86–100. doi: 10.1084/jem.145.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Takahashi M., Takahashi S., Brade V., Nussenzweig V. Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest. 1978 Aug;62(2):349–358. doi: 10.1172/JCI109135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yasmeen D., Ellerson J. R., Dorrington K. J., Painter R. H. The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1. J Immunol. 1976 Feb;116(2):518–526. [PubMed] [Google Scholar]
  24. Yonemasu K., Stroud R. M. Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies. J Immunol. 1971 Feb;106(2):304–313. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES